Current knowledge of the involvement of FGFs and FGFRs in the development of cancer cell resistance to this broad group of anticancer agents is limited to a few studies describing a correlation between FGF2/FGFR1 activity and the acquisition of insensitivity to paclitaxel (12, 28, 29), most likely through stimulation of the PI3K/AKT pathway (29). Here, AKT1 is linked to cancer.